Pharmacogenetic aspect of intravitreal ranibizumab treatment in neovascular age-related macular degeneration: a five-year follow-up

Yükleniyor...
Küçük Resim

Tarih

2018

Yazarlar

Şengül, Elvan Alper
Artunay, Özgür
Rasier, Rıfat
Koçkar, Alev
Afacan, Ceyda
Hançer, Veysel Sabri
Yuzbaşıoğlu, Erdal

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Taylor & Francis Inc

Erişim Hakkı

info:eu-repo/semantics/closedAccess

Özet

Purpose: This study aims to evaluate the role of complement factor H (CFH) in response to intravitreal ranibizumab (IVR) treatment, which is administered to patients with neovascular age-related macular degeneration (nAMD).Methods: In this retrospective study, 90 nAMD patients' 90 eyes were evaluated. IVR was injected once a month for three consecutive months, and then, patients were followed up for five years by using pro re nata method.Results: Average visual acuity (BCVA) values in TT group for the third, fourth and fifth years were found to be significantly higher than those in TC and CC groups, while average BCVA values in TC group were significantly higher than those in CC group (all p = .000 < .0167).Conclusion: Patients with CFH TT genotype responded significantly better to treatment after third year, while patients with CC genotype had a poorer response to IVR.

Açıklama

Anahtar Kelimeler

Age-Related Macular Degeneration, Complement Factor H Polymorphism, Genetics, Inflammation, Intravitreal Ranibizumab

Kaynak

Ocular Immunology and Inflammation

WoS Q Değeri

Q2

Scopus Q Değeri

Q1

Cilt

26

Sayı

6

Künye

Sengul, E. A., Artunay, O., Rasier, R., Kockar, A., Afacan, C., Hancer, V. S., & Yuzbasioglu, E. (2018). Pharmacogenetic aspect of intravitreal ranibizumab treatment in neovascular age-related macular degeneration: a five-year follow-up. Ocular immunology and inflammation, 26(6), 971-977.